Search Results for "arterial"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for arterial. Results 41 to 50 of 210 total matches.

Fenfluramine (Fintepla) for Dravet Syndrome

   
The Medical Letter on Drugs and Therapeutics • Aug 09, 2021  (Issue 1630)
was associated with an increased risk of pulmonary arterial hypertension and cardiac valvulopathy.7 The labeling ...
The FDA has approved fenfluramine oral solution (Fintepla – Zogenix) for treatment of seizures in patients ≥2 years old with Dravet syndrome. It is the third drug to be approved for this indication. Stiripentol (Diacomit) and cannabidiol (Epidiolex), a purified product derived from marijuana, were approved earlier.
Med Lett Drugs Ther. 2021 Aug 9;63(1630):126-8 |  Show IntroductionHide Introduction

Cilostazol for Intermittent Claudication

   
The Medical Letter on Drugs and Therapeutics • May 07, 1999  (Issue 1052)
Administration for treatment of intermittent claudication due to occlusive peripheral arterial disease ...
Cilostazol, a phosphodiesterase III inhibitor that has been used in Japan since 1988, has been approved by the FDA for treatment on intermittent claudication due to occlusive peripheral arterial disease.
Med Lett Drugs Ther. 1999 May 7;41(1052):44-6 |  Show IntroductionHide Introduction

Treatment of Atrial Fibrillation

   
The Medical Letter on Drugs and Therapeutics • Jan 08, 2024  (Issue 1693)
for rate control in patients with coronary artery disease or systolic dysfunction. Verapamil or diltiazem ...
Atrial fibrillation (AF) is the most common arrhythmia in the world. Risk factor modification, anticoagulation, rhythm control, and rate control are the four pillars of its management. American College of Cardiology/American Heart Association (ACC/AHA) guidelines on management of AF were updated recently.
Med Lett Drugs Ther. 2024 Jan 8;66(1693):1-8   doi:10.58347/tml.2024.1693a |  Show IntroductionHide Introduction

Lepirudin for Heparin-Induced Thrombocytopenia

   
The Medical Letter on Drugs and Therapeutics • Sep 25, 1998  (Issue 1036)
, producing a prothrombotic state. Untreated HIT can lead to venous and arterial thrombosis, pulmonary ...
Lepirudin (Refludan - Hoechst Marion Roussel), a direct inhibitor of thrombin, has been approved by the FDA for use as an anticoagulant in patients with heparin-induced thrombocytopenia and thromboembolic complications.
Med Lett Drugs Ther. 1998 Sep 25;40(1036):94-5 |  Show IntroductionHide Introduction

Durlaza - A 24-Hour Extended-Release Aspirin

   
The Medical Letter on Drugs and Therapeutics • Jan 18, 2016  (Issue 1486)
with diabetes and coronary artery disease (CAD) may have high platelet turnover; a study in patients with CAD ...
The FDA has approved Durlaza (New Haven Pharmaceuticals), a 24-hour extended-release (ER) aspirin formulation available only by prescription, for secondary prevention of myocardial infarction (MI) and stroke.
Med Lett Drugs Ther. 2016 Jan 18;58(1486):7 |  Show IntroductionHide Introduction

Drugs for Intermittent Claudication

   
The Medical Letter on Drugs and Therapeutics • Feb 16, 2004  (Issue 1176)
symptom of peripheral arterial disease (PAD), involves both risk factor modification and symptomatic ...
Management of intermittent claudication, the most common symptom of peripheral arterial disease (PAD), involves both risk factor modification and symptomatic treatment (WR Hiatt, N Engl J Med 2001; 344:1608; RM Schainfeld, J Am Board Fam Pract 2001; 14:443).
Med Lett Drugs Ther. 2004 Feb 16;46(1176):13-5 |  Show IntroductionHide Introduction

A New Dihydroergotamine Nasal Spray (Trudhesa) for Migraine

   
The Medical Letter on Drugs and Therapeutics • Dec 27, 2021  (Issue 1640)
Dihydroergotamine is a weaker arterial vasoconstrictor than ergotamine and causes fewer serious adverse effects ...
The FDA has approved Trudhesa (Impel Neuropharma), a new dihydroergotamine nasal spray product, for acute treatment of migraine with or without aura in adults. Another dihydroergotamine nasal spray (Migranal, and generics) has been available for many years for the same indication.
Med Lett Drugs Ther. 2021 Dec 27;63(1640):204-7 |  Show IntroductionHide Introduction

Fenoldopam--A New Drug for Parenteral Treatment of Severe Hypertension

   
The Medical Letter on Drugs and Therapeutics • May 22, 1998  (Issue 1027)
in spite of the decrease in arterial pressure. In addition, fenoldopam has direct natriuretic and diuretic ...
Fenoldopam mesylte (Corlopam - Neurex), a peripheral dopamine-1 (DA1) agonist, has been approved by the FDA for parenteral use in lowering blood pressure. The manufacturer claims that, unlike other parenteral antihypertensive agents, fenoldopam not only lowers blood pressure but also maintains or improves renal function.
Med Lett Drugs Ther. 1998 May 22;40(1027):57-8 |  Show IntroductionHide Introduction

Dezocine

   
The Medical Letter on Drugs and Therapeutics • Oct 19, 1990  (Issue 829)
, pulmonary artery pressure, and left ventricular stroke work, and some Medical Letter consultants believe ...
Dezocine (Dalgan - Astra), a new synthetic opioid agonist/antagonist structurally related to pentazocine (Talwin), was recently approved for parenteral use as an analgesic by the US Food and Drug Administration.
Med Lett Drugs Ther. 1990 Oct 19;32(829):95-6 |  Show IntroductionHide Introduction

Laparoscopic Cholecystectomy

   
The Medical Letter on Drugs and Therapeutics • Dec 28, 1990  (Issue 834)
duct and artery are separated, clipped, and divided. The gall bladder is dissected free ...
Unlike new drugs, new techniques for surgery do not need the approval of any government agency. Laparoscopic cholecystectomy, made possible by the development of miniaturized television cameras, is one such technique that has recently attracted widespread interest (LW Way, N Engl J Med, 323:1273, Nov 1, 1990; R Winslow, Wall St J, 216:1, Dec 10, 1990).
Med Lett Drugs Ther. 1990 Dec 28;32(834):115-6 |  Show IntroductionHide Introduction